The CLL-related Tregs functionality was finally confirmed in the in vivo experiment with TCL1-OVA cells, indicating that Tregs inhibit the proliferation of CD8+ cells upon recognition of tumor-expressed antigen. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.